Editas Medicine Inc. (NASDAQ:EDIT) saw unusually-strong trading volume on Friday . Approximately 185,902 shares changed hands during trading, an increase of 33% from the previous session’s volume of 139,660 shares.The stock last traded at $27.25 and had previously closed at $25.84.

A number of research analysts have weighed in on EDIT shares. Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Vetr raised Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price for the company in a report on Monday, May 9th. Zacks Investment Research raised Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Jefferies Group reaffirmed a “hold” rating and set a $35.00 target price on shares of Editas Medicine in a report on Friday, June 10th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Editas Medicine has a consensus rating of “Hold” and a consensus price target of $33.50.

The firm’s market capitalization is $954.38 million. The company has a 50-day moving average of $27.73 and a 200 day moving average of $30.28.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Monday, May 16th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.50. The company earned $0.80 million during the quarter, compared to analysts’ expectations of $1.08 million. On average, equities research analysts forecast that Editas Medicine Inc. will post ($2.35) EPS for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.